View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 28, 2022

BerGenBio, Oslo University Hospital to test bemcentinib in hospitalised Covid-19 patients

EU-SolidAct has a master protocol designed to analyse potential therapies in Covid-19 patients.

BerGenBio and Oslo University Hospital in Norway have executed a collaborative agreement to analyse the former’s AXL inhibitor, bemcentinib, in a trial in hospitalised Covid-19 patients.

Named European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (EU-SolidAct), the randomised, multicentre, adaptive Phase II and III platform trial is part of EU-RESPONSE. 

A pan-European research project, EU-RESPONSE is associated with the quick and synchronised analysis of therapies for treating Covid-19.

With study centres established in 15 countries, EU-SolidAct has a master protocol designed to analyse potential therapies in hospitalised Covid-19 patients.

The trial is sponsored by Oslo University Hospital along with the Institut National de la Santé Et de la Recherche Médicale (Inserm), France and the European Clinical Research Infrastructure Network (ECRIN). 

In the trial, bemcentinib will be assessed in up to 500 such individuals. 

Bemcentinib was opted as the second compound to be studied in the EU-SolidAct platform by an international expert group. 

To support the study, BerGenBio will offer bemcentinib drug material as well as incremental funding of expenses linked to the sub-protocol of the therapy. 

Initially, Eli Lilly and Company’s baricitinib was evaluated under the EU-SolidAct platform as the first drug.

Baricitinib is currently being examined for market authorisation by the European Medicines Agency (EMA) for usage in Covid-19 patients in the hospital setting. 

BerGenBio CEO Martin Olin said: “As the Covid-19 pandemic continues to evolve, it is even more important to identify new therapies for hospitalised patients that have a mechanism of action effective across disease variants. 

“The EU-SolidAct platform provides BerGenBio with a unique opportunity to rapidly study the effectiveness of bemcentinib and to evaluate the promising signals of efficacy that were observed in the hospitalised patients requiring oxygen in earlier studies.”

In September last year, the company concluded enrolment of participants in a Phase Ib/II BGBC003 trial of bemcentinib to treat patients with acute myeloid leukaemia and myelodysplastic syndrome.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy